Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Work In Process (2022 - 2025)

Historic Work In Process for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $12.9 million.

  • Axsome Therapeutics' Work In Process rose 5687.26% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 5687.26%. This contributed to the annual value of $7.7 million for FY2024, which is 2492.47% down from last year.
  • Per Axsome Therapeutics' latest filing, its Work In Process stood at $12.9 million for Q3 2025, which was up 5687.26% from $7.5 million recorded in Q2 2025.
  • Axsome Therapeutics' Work In Process' 5-year high stood at $14.0 million during Q4 2022, with a 5-year trough of $6.8 million in Q1 2025.
  • Moreover, its 4-year median value for Work In Process was $10.3 million (2023), whereas its average is $10.1 million.
  • The largest annual percentage gain for Axsome Therapeutics' Work In Process in the last 5 years was 5687.26% (2025), contrasted with its biggest fall of 3763.65% (2025).
  • Axsome Therapeutics' Work In Process (Quarter) stood at $14.0 million in 2022, then fell by 26.34% to $10.3 million in 2023, then fell by 24.92% to $7.7 million in 2024, then soared by 66.4% to $12.9 million in 2025.
  • Its Work In Process stands at $12.9 million for Q3 2025, versus $7.5 million for Q2 2025 and $6.8 million for Q1 2025.